OBJECTIVES: The objective of the study was to determine the relative bioavailability of an extended-release multilayer bead formulation of methylphenidate hydrochloride (MPH-MLR) 80 mg vs. methylphenidate immediate-release (IR; Ritalin(®)) tablets as single and multiple doses in the fed state. METHODS: A single-center, multiple-dose, randomized, open-label, two-period crossover study conducted in 26 healthy adults assigned to4 days of once-daily MPH-MLR 80 mg or IR methylphenidate 25 mg three times daily. RESULTS: MPH-MLR 80 mg produced reproducible biphasic profiles of plasma methylphenidate concentrations characterized by a rapid initial peak, followed by a moderate decline reaching a plateau ~5 h post dose, then a gradual increase culminating in an attenuated second peak ~7 h post dose. Maximum concentration was lower for MPH-MLR 80 mg than IR methylphenidate 25 mg three times daily on day 1 (23.70 vs. 31.47 ng/mL); exposure was similar. The geometric mean ratios (MPH-MLR/IR methylphenidate [90 % CI]) of log-transformed area under the plasma drug concentration-time curve to the last measurable observation (day 1: 0.88 [84.75-91.80]; day 4: 0.84 [81.16-86.94]), and area under the plasma drug concentration extrapolated to infinity (day 1: 0.93 [88.57-97.28]; day 4: 0.88 [84.48-91.17]) were within the 80-125 % bioequivalence range. The mean ± SD MPH-MLR 80-mg capsule day 4 area under the plasma drug concentration vs. time curve from 0 to 4 h (74.5 ± 15.2 ng·h/mL) was greater than IR methylphenidate 25 mg three times daily (66.0 ± 17.4 ng·h/mL), confirming steady-state levels during the study period. All treatment regimens were safe and well tolerated. CONCLUSION:MPH-MLR 80-mg capsule once daily or IRmethylphenidate 25 mg three times daily provides comparable maximum methylphenidate concentrations and systemic exposure in the fed state.
RCT Entities:
OBJECTIVES: The objective of the study was to determine the relative bioavailability of an extended-release multilayer bead formulation of methylphenidate hydrochloride (MPH-MLR) 80 mg vs. methylphenidate immediate-release (IR; Ritalin(®)) tablets as single and multiple doses in the fed state. METHODS: A single-center, multiple-dose, randomized, open-label, two-period crossover study conducted in 26 healthy adults assigned to 4 days of once-daily MPH-MLR 80 mg or IR methylphenidate 25 mg three times daily. RESULTS: MPH-MLR 80 mg produced reproducible biphasic profiles of plasma methylphenidate concentrations characterized by a rapid initial peak, followed by a moderate decline reaching a plateau ~5 h post dose, then a gradual increase culminating in an attenuated second peak ~7 h post dose. Maximum concentration was lower for MPH-MLR 80 mg than IR methylphenidate 25 mg three times daily on day 1 (23.70 vs. 31.47 ng/mL); exposure was similar. The geometric mean ratios (MPH-MLR/IR methylphenidate [90 % CI]) of log-transformed area under the plasma drug concentration-time curve to the last measurable observation (day 1: 0.88 [84.75-91.80]; day 4: 0.84 [81.16-86.94]), and area under the plasma drug concentration extrapolated to infinity (day 1: 0.93 [88.57-97.28]; day 4: 0.88 [84.48-91.17]) were within the 80-125 % bioequivalence range. The mean ± SD MPH-MLR 80-mg capsule day 4 area under the plasma drug concentration vs. time curve from 0 to 4 h (74.5 ± 15.2 ng·h/mL) was greater than IR methylphenidate 25 mg three times daily (66.0 ± 17.4 ng·h/mL), confirming steady-state levels during the study period. All treatment regimens were safe and well tolerated. CONCLUSION: MPH-MLR 80-mg capsule once daily or IR methylphenidate 25 mg three times daily provides comparable maximum methylphenidate concentrations and systemic exposure in the fed state.
Authors: Mark Wolraich; Lawrence Brown; Ronald T Brown; George DuPaul; Marian Earls; Heidi M Feldman; Theodore G Ganiats; Beth Kaplanek; Bruce Meyer; James Perrin; Karen Pierce; Michael Reiff; Martin T Stein; Susanna Visser Journal: Pediatrics Date: 2011-10-16 Impact factor: 7.124
Authors: Russell Schachar; Abel Ickowicz; Jennifer Crosbie; Graeme A E Donnelly; Joseph L Reiz; Paula C Miceli; Zoltan Harsanyi; Andrew C Darke Journal: J Child Adolesc Psychopharmacol Date: 2008-02 Impact factor: 2.576
Authors: Matthew Brams; John Turnbow; Linda Pestreich; John Giblin; Ann Childress; Kevin McCague; Rafael Muniz Journal: J Clin Psychopharmacol Date: 2012-10 Impact factor: 3.153
Authors: Sharon B Wigal; Laurence L Greenhill; Earl Nordbrock; Daniel F Connor; Scott H Kollins; Akwete Adjei; Ann Childress; Annamarie Stehli; Robert J Kupper Journal: J Child Adolesc Psychopharmacol Date: 2014-12 Impact factor: 2.576
Authors: Nathan S Teuscher; Akwete Adjei; Robert L Findling; Laurence L Greenhill; Robert J Kupper; Sharon Wigal Journal: Drug Des Devel Ther Date: 2015-05-26 Impact factor: 4.162
Authors: Ann C Childress; Scott H Kollins; Henry C Foehl; Jeffrey H Newcorn; Greg Mattingly; Robert J Kupper; Akwete L Adjei Journal: J Child Adolesc Psychopharmacol Date: 2019-12-03 Impact factor: 2.576